Look back at pharma news in week to January 25

27 January 2019

By Barbara Obstoj-Cardwell

Having been somewhat slow on approving biosimilars, the US Food and Drug Administration last week added clearance to a third version of Roche’s Herceptin, Samsung Bioepis’ Ontruzant. On the research front, Aurinia Pharmaceuticals is pushing ahead with its dry eye therapy candidate voclosporin despite disappointing trial data. Also last week, the UK government set out plans to help control antibiotic resistance, including a new payment model. Additionally, the fourth-quarter 2018 financial results season kicked off, with disappointing figures from AbbVie and mixed ones from Johnson & Johnson.

FDA approves third biosimilar of Roche’s Herceptin

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK